Shots: FDC has launched two variants of Favipiravir under the brand names PiFLU and Favenza to treat mild to moderate COVID-19 in India. The products will be available across the country Both the variant will be available at $0.74 (Rs. 55) /tablet. The DCGI had earlier approved the use of Favipiravir as an off-patent, oral […]Read More
Shots: Jenburkt became the second company to launch Favivent (favipiravir) to treat mild to moderate COVID-19 symptoms at a price of Rs. 39/tablet Cipla receives the DCGI approval for Ciplenza (favipiravir, 200mg) targeting the unmet medical needs for COVID-19 treatment options in the country through restricted emergency use. The company will launch Ciplenza in the […]Read More
Shots: The P-III study assessing the efficacy and safety of Favipiravir + SSC vs SCC in 150 mild to moderate patients, randomized within a 48hour window of testing RT-PCR positive for COVID-19 Results: P-III study the improvement in 1EPs with 28.6% faster viral clearance in the overall population as measured by the median time until […]Read More
Shots: Fujifilm to receive upfront, license fee along with royalties on sales of the therapy. Dr. Reddy’s and GRA to get the exclusive right to develop & commercialize Avigan globally (Ex- Japan). Additionally, Dr. Reddy’s would have exclusive rights for the therapy in India Fujifilm will provide pre/ clinical data of Avigan to Dr. Reddy’s […]Read More
Shots: Glenmark has received manufacturing and marketing approval for its antiviral drug FabiFlu (favipiravir) to treat COVID-19 in India. The drug will be available as a prescribed therapy for INR 103/tablet with recommended dose being 1800mg (bid) on day 1, followed by 800mg (bid) up to day 14 Favipiravir demonstrated clinical improvements of up to […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
